Advertisement

  1. National

Breast cancer drug 'too expensive' for NHS

A drug that can extend the lives of some women with advanced breast cancer has been rejected for NHS use because it is too expensive.

Kadcyal can give patients with HER2-positive breast cancer which has spread to other parts of the body and where initial treatments have failed an additional six months of life.

The National Institute for Health and Care Excellence (Nice) said the drug was too expensive to recommend for widespread use in the health service.

View all 5 updates ›

NHS won't offer 'last hope' breast cancer drug

The NHS financial watchdog, Nice, has decided Kadcyla is too expensive. Credit: PA

The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.

Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.

However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.

The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.

Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.

More top news